Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Bit Bio Limited maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area, which currently includes 1 pending office action. This single active case is assigned to 1 distinct examiner and 1 distinct art unit. This structure reflects a focused prosecution profile, where the company's current patent office activity is limited to a single technical and administrative path.
The busiest examiner for this portfolio is BRETZ, COREY LANE, who holds 1 busiest examiner pending action. This matches the total of 1 pending office action for the company, making this examiner the sole official reviewing the company's active applications. The outcome of the 1 pending office action will be determined by the specific examination standards applied by this individual within the Biotechnology & Pharmaceuticals field.
With 1 distinct examiner and 1 distinct art unit, the prosecution environment is highly concentrated. There are no other active matters to provide a baseline for comparison or to diversify the company's exposure across different examiners. The relationship between the examiner and the pending workload simplifies the management of the 1 pending office action but places significant importance on the resolution of this single case.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRETZ, COREY LANE | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17815928 | SAFE HARBOR LOCI | BRETZ, COREY LANE | — |
| Art Unit | Apps |
|---|---|
| 1600 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17815928 | SAFE HARBOR LOCI | BRETZ, COREY LANE | 1600 | §103 | Final Rejection | — | Pending | Jul 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBit Bio Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Corey Lane Bretz has the most, with 1 of Bit Bio Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
